{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:21:03Z","timestamp":1792686063017,"version":"4.5.0"},"reference-count":222,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["lzujbky-2023-ct06"],"award-info":[{"award-number":["lzujbky-2023-ct06"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160148"],"award-info":[{"award-number":["82160148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.critrevonc.2026.105275","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:14:08Z","timestamp":1773458048000},"page":"105275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Progress and challenges in CAR-T cell therapy for bladder cancer"],"prefix":"10.1016","volume":"222","author":[{"given":"Kun","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongze","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueming","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4919-8164","authenticated-orcid":false,"given":"Zhilong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105275_bib1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12964-024-01995-y","article-title":"MDSC: a new potential breakthrough in CAR-T therapy for solid tumors","volume":"22","author":"Abdalsalam","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.critrevonc.2026.105275_bib2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/bju.12727","article-title":"Significance of MUC1 in bladder cancer: science made simple","volume":"115","author":"Ahmad","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.critrevonc.2026.105275_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4196\/kjpp.2023.27.3.241","article-title":"MST1R as a potential new target antigen of chimeric antigen receptor T cells to treat solid tumors","volume":"27","author":"An","year":"2023","journal-title":"Korean J. Physiol. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105275_bib5","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1038\/s41467-024-47799-z","article-title":"CAR affinity modulates the sensitivity of CAR-T cells to PD-1\/PD-L1-mediated inhibition","volume":"15","author":"Andreu-Saumell","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105275_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2019.01.003","article-title":"Small Leucine Rich Proteoglycans (decorin, biglycan and lumican) in cancer","volume":"491","author":"Appunni","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.critrevonc.2026.105275_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s44318-024-00309-9","article-title":"An EpCAM\/Trop2 mechanostat differentially regulates collective behaviour of human carcinoma cells","volume":"44","author":"Aslemarz","year":"2024","journal-title":"EMBO J."},{"key":"10.1016\/j.critrevonc.2026.105275_bib8","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-025-02386-8","article-title":"Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives","volume":"24","author":"Azeez","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105275_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007426","article-title":"HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity","volume":"11","author":"Bassan","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105275_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1275375","article-title":"Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer","volume":"14","author":"Bazargan","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib11","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/ijms20061283","article-title":"Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"IJMS"},{"key":"10.1016\/j.critrevonc.2026.105275_bib12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41571-025-00992-5","article-title":"Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma","volume":"22","author":"Bock","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.672262","article-title":"Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics","volume":"11","author":"Bogen","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11912-023-01360-1","article-title":"Nectin-4: a Tumor Cell Target and Status of Inhibitor Development","volume":"25","author":"Bouleftour","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105275_bib15","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105275_bib16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib17","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2026.105275_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13287-022-02719-0","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress","volume":"13","author":"Budi","year":"2022","journal-title":"Stem Cell Res Ther."},{"key":"10.1016\/j.critrevonc.2026.105275_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102868","article-title":"CAR-T cell therapy for breast cancer: current status and future perspective","volume":"133","author":"Buono","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105275_bib20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3389\/fonc.2020.00699","article-title":"Inhibition of Histone Deacetylase (HDAC) enhances checkpoint blockade efficacy by rendering bladder cancer cells visible for T cell-mediated destruction","volume":"10","author":"Burke","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib21","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.3390\/medicina58111624","article-title":"Micro-ultrasound in the diagnosis and staging of prostate and bladder cancer: a comprehensive review","volume":"58","author":"Calace","year":"2022","journal-title":"Medicina"},{"key":"10.1016\/j.critrevonc.2026.105275_bib22","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.canlet.2017.11.015","article-title":"TM4SF1 regulates apoptosis, cell cycle and ROS metabolism via the PPAR\u03b3-SIRT1 feedback loop in human bladder cancer cells","volume":"414","author":"Cao","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105275_bib23","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.euo.2023.02.011","article-title":"Cancer-associated fibroblasts in bladder cancer: origin, biology, and therapeutic opportunities","volume":"6","author":"Caramelo","year":"2023","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103595","article-title":"Cellular and molecular mechanisms implicated in the dual role of ROR2 in cancer","volume":"170","author":"Castro","year":"2022","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib25","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.3390\/cancers14082037","article-title":"The MST1R\/RON tyrosine kinase in cancer: oncogenic functions and therapeutic strategies","volume":"14","author":"Cazes","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105275_bib26","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2490078","article-title":"Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody\u2013drug conjugate","volume":"17","author":"Chang","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.critrevonc.2026.105275_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-025-09212-7","article-title":"Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery","author":"Chen","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105275_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101140","article-title":"Sialylated IgG-activated integrin \u03b24-Src-Erk axis stabilizes c-Myc in a p300 lysine acetyltransferase-dependent manner to promote colorectal cancer liver metastasis","volume":"61","author":"Chen","year":"2025","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2026.105275_bib29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","article-title":"Turning foes to friends: targeting cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2026.105275_bib30","first-page":"21","article-title":"The application of HER2 and CD47 CAR-macrophage in ovarian cancer","author":"Chen","year":"2023","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.critrevonc.2026.105275_bib31","doi-asserted-by":"crossref","first-page":"12366","DOI":"10.3390\/ijerph191912366","article-title":"Price and prejudice? The value of Chimeric Antigen Receptor (CAR) T-Cell Therapy","volume":"19","author":"Choi","year":"2022","journal-title":"IJERPH"},{"key":"10.1016\/j.critrevonc.2026.105275_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1290488","article-title":"CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma","volume":"14","author":"Ciulean","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib33","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1973783","article-title":"Innate-like NKp30+ CD8+ T cells armed with TCR\/CAR target tumor heterogeneity","volume":"10","author":"Correia","year":"2021","journal-title":"OncoImmunology"},{"key":"10.1016\/j.critrevonc.2026.105275_bib34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3390\/diagnostics12020431","article-title":"A Comparative study of the triglycerides\/HDL ratio and pseudocholinesterase levels in patients with bladder cancer","volume":"12","author":"Crocetto","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.critrevonc.2026.105275_bib35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/JS9.0000000000000200","article-title":"Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer","volume":"109","author":"Cui","year":"2023","journal-title":"Int J. Surg."},{"key":"10.1016\/j.critrevonc.2026.105275_bib36","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.critrevonc.2026.105275_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-59621-5","article-title":"USP2 inhibition unleashes CD47-restrained phagocytosis and enhances anti-tumor immunity","volume":"16","author":"Dai","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105275_bib38","doi-asserted-by":"crossref","DOI":"10.37349\/etat.2025.1002304","article-title":"Key immune cells and their crosstalk in the tumor microenvironment of bladder cancer: insights for innovative therapies","volume":"6","author":"Di Spirito","year":"2025","journal-title":"Explor. Target. AntiTumor Ther."},{"key":"10.1016\/j.critrevonc.2026.105275_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202400156","article-title":"Novel CAR-T Cells Specifically Targeting SIA-CIgG Demonstrate Effective Antitumor Efficacy in Bladder Cancer","volume":"11","author":"Ding","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.critrevonc.2026.105275_bib40","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s00345-015-1557-9","article-title":"Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups","volume":"33","author":"Ding","year":"2015","journal-title":"World J. Urol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib41","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2026.105275_bib42","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105275_bib43","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/cas.15631","article-title":"Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7","volume":"114","author":"Fan","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2026.105275_bib44","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/2159-8290.CD-24-0417","article-title":"Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy","volume":"15","author":"Febres-Aldana","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105275_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.00202","article-title":"Role of Transmembrane 4 L Six Family 1 in the Development and Progression of Cancer","volume":"7","author":"Fu","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.critrevonc.2026.105275_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1448752","article-title":"High specificity of engineered T cells with third generation CAR (CD28-4-1BB-CD3-\u03b6) based on biotin-bound monomeric streptavidin for potential tumor immunotherapy","volume":"15","author":"Gallego-Valle","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216726","article-title":"PD-1 regulation in immune homeostasis and immunotherapy","volume":"588","author":"Gao","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105275_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009611","article-title":"CAR-T cell therapy in developing countries: how long should we wait?","volume":"12","author":"Gautam","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105275_bib49","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1016\/j.cell.2025.03.041","article-title":"Immunotherapy-related cognitive impairment after CAR T cell therapy in mice","volume":"188","author":"Geraghty","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105275_bib50","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrurol.2016.224","article-title":"Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer","volume":"14","author":"Gorin","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib51","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41698-025-01016-2","article-title":"Mucin-1: a promising pan-cancer therapeutic target","volume":"9","author":"Grewal","year":"2025","journal-title":"npj Precis. Onc."},{"key":"10.1016\/j.critrevonc.2026.105275_bib52","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2026.105275_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.782448","article-title":"Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells","volume":"12","author":"Grunewald","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib54","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1186\/s12967-025-06523-1","article-title":"Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory\/relapsed gliomas","volume":"23","author":"Gu","year":"2025","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.critrevonc.2026.105275_bib55","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.3389\/fimmu.2018.02460","article-title":"CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge","volume":"9","author":"Guedan","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib56","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","article-title":"CAR-T Therapies in Solid Tumors: Opportunities and Challenges","volume":"25","author":"Guzman","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105275_bib57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","article-title":"The biology and rationale of targeting nectin-4 in urothelial carcinoma","volume":"18","author":"Heath","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.103020","article-title":"Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors","volume":"84","author":"Hong","year":"2023","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-022-05067-2","article-title":"TM4SF1 promotes esophageal squamous cell carcinoma metastasis by interacting with integrin \u03b16","volume":"13","author":"Hou","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105275_bib60","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-025-02052-3","article-title":"Sialylated IgG expressed in triple-negative breast cancer cells promotes cancer progression by promoting glycolysis","volume":"27","author":"Hu","year":"2025","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105275_bib61","article-title":"Redefining bladder cancer treatment: innovations in overcoming drug resistance and immune evasion","volume":"16","author":"Huang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib62","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.3390\/biomedicines12092152","article-title":"Targeting CD47 and Angiogenesis Demonstrates Effective Anti-Tumor Effect in Bladder Cancer","volume":"12","author":"Huang","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105275_bib63","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1158\/0008-5472.CAN-22-2733","article-title":"A Self-Propagating c-Met\u2013SOX2 Axis Drives Cancer-Derived IgG Signaling That Promotes Lung Cancer Cell Stemness","volume":"83","author":"Huang","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105275_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.70025","article-title":"Enhancing CAR T-cell therapy manufacturing efficiency through semi-automated bioprocessing","volume":"14","author":"Isaacson","year":"2025","journal-title":"Clin. & Trans. Imm"},{"key":"10.1016\/j.critrevonc.2026.105275_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216780","article-title":"Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer","volume":"588","author":"Jabbarzadeh Kaboli","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105275_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1498391","article-title":"c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity","volume":"15","author":"Jabbarzadeh Kaboli","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2025.06.007","article-title":"Chimeric Antigen Receptor (CAR) T-cell Therapy: Engineering Immune Cells To Treat Liver Diseases","author":"Jaeckel","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib68","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/s44321-024-00055-9","article-title":"Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models","volume":"16","author":"Jamali","year":"2024","journal-title":"EMBO Mol. Med"},{"key":"10.1016\/j.critrevonc.2026.105275_bib69","doi-asserted-by":"crossref","DOI":"10.1039\/D4MD00799A","article-title":"A momentous progress update: epidermal growth factor receptor inhibitors as viable agents for combating cancer","author":"Jangra","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105275_bib70","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/CU9.0000000000000219","article-title":"Patient-derived bladder cancer organoid model to predict sensitivity and feasibility of tailored precision therapy","volume":"17","author":"Jiang","year":"2023","journal-title":"Curr. Urol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib71","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/cancers12051075","article-title":"Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers","volume":"12","author":"Kailayangiri","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105275_bib72","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.3390\/cells10113194","article-title":"Macrophage Reprogramming and Cancer Therapeutics: Role of iNOS-Derived NO","volume":"10","author":"Kashfi","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105275_bib73","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1038\/s41418-023-01235-9","article-title":"Targeting isoforms of RON kinase (MST1R) drives antitumor efficacy","volume":"30","author":"Kim","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.critrevonc.2026.105275_bib74","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3390\/cancers16051056","article-title":"Pancreatic Cancer Treatment Targeting the HGF\/c-MET Pathway: The MEK Inhibitor Trametinib","volume":"16","author":"Kim","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105275_bib75","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12943-023-01897-6","article-title":"The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer","volume":"22","author":"Komura","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105275_bib76","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12967-022-03442-3","article-title":"Exhaustion of CAR T cells: potential causes and solutions","volume":"20","author":"Kouro","year":"2022","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.critrevonc.2026.105275_bib77","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3390\/cells10051170","article-title":"Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy","volume":"10","author":"Krishnamoorthy","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105275_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/5575260","article-title":"Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell Metastasis","volume":"2021","author":"La","year":"2021","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105275_bib79","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105275_bib80","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/bjh.18797","article-title":"Anti-PD -1 therapy can possibly reverse CAR T cells exhaustion in DLBCL","volume":"202","author":"Lamure","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib81","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2158013","article-title":"Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors","volume":"12","author":"Laurent","year":"2023","journal-title":"OncoImmunology"},{"key":"10.1016\/j.critrevonc.2026.105275_bib82","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.3390\/cancers13215297","article-title":"Tumor Heterogeneity and Consequences for Bladder Cancer Treatment","volume":"13","author":"Lavallee","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105275_bib83","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35966","article-title":"The current and future role of systemic therapy in non\u2013muscle-invasive bladder cancer","volume":"131","author":"Lazarovich","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105275_bib84","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41585-022-00608-y","article-title":"The dynamic roles of the bladder tumour microenvironment","volume":"19","author":"Lee","year":"2022","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib85","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1158\/1078-0432.CCR-20-2487","article-title":"A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3\u2013Specific CAR T Cells in Solid Tumors","volume":"27","author":"Lei","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105275_bib86","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s11255-016-1264-5","article-title":"Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer","volume":"48","author":"Li","year":"2016","journal-title":"Int Urol. Nephrol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib87","article-title":"Therapeutic prospects of nectin-4 in cancer: applications and value","volume":"14","author":"Li","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib88","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1016\/j.apsb.2024.07.003","article-title":"Strategies for intravesical drug delivery: From bladder physiological barriers and potential transport mechanisms","volume":"14","author":"Li","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.critrevonc.2026.105275_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202303230","article-title":"Cancer-Associated Fibroblast-Induced Remodeling of Tumor Microenvironment in Recurrent Bladder Cancer","volume":"10","author":"Liang","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.critrevonc.2026.105275_bib90","doi-asserted-by":"crossref","first-page":"12296","DOI":"10.1021\/acs.jmedchem.4c02626","article-title":"Prodrugs Targeting Prostate-Specific Membrane Antigen against Prostate Cancer","volume":"68","author":"Liolios","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105275_bib91","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jare.2023.10.009","article-title":"Deciphering the role of CD47 in cancer immunotherapy","volume":"63","author":"Liu","year":"2024","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.critrevonc.2026.105275_bib92","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-024-00490-x","article-title":"Challenges and strategies associated with CAR-T cell therapy in blood malignancies","volume":"13","author":"Liu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib93","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/cancers13010131","article-title":"Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer","volume":"13","author":"Lopez-Beltran","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105275_bib94","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105275_bib95","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41467-019-14050-z","article-title":"Intratumoral heterogeneity and clonal evolution in liver cancer","volume":"11","author":"Losic","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105275_bib96","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-024-02512-6","article-title":"BCMA\/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma","volume":"22","author":"Lu","year":"2024","journal-title":"J. Nanobiotechnol"},{"key":"10.1016\/j.critrevonc.2026.105275_bib97","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-025-02334-6","article-title":"Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy","volume":"24","author":"Lu","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105275_bib98","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1186\/s12889-024-19909-5","article-title":"The disease burden of bladder cancer and its attributable risk factors in five Eastern Asian countries, 1990\u20132019: a population-based comparative study","volume":"24","author":"Luo","year":"2024","journal-title":"BMC Public Health"},{"key":"10.1016\/j.critrevonc.2026.105275_bib99","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.3390\/cimb45110566","article-title":"Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer","volume":"45","author":"Ma","year":"2023","journal-title":"CIMB"},{"key":"10.1016\/j.critrevonc.2026.105275_bib100","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105275_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115638","article-title":"Harnessing epigenetic inhibitors: A promising approach for overcoming challenges in pancreatic ductal adenocarcinoma treatment","volume":"224","author":"Maietta","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.critrevonc.2026.105275_bib102","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor Antigen Escape from CAR T-cell Therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105275_bib103","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.humpath.2007.02.018","article-title":"Arginine metabolism in tumor-associated macrophages in cutaneous malignant melanoma: evidence from human and experimental tumors","volume":"38","author":"Massi","year":"2007","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib104","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1078-0432.CCR-24-1977","article-title":"Mucin 5AC Promotes Breast Cancer Brain Metastasis through cMET\/CD44v6","volume":"31","author":"Maurya","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105275_bib105","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/hum.2020.278","article-title":"Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy","volume":"32","author":"McGrath","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.critrevonc.2026.105275_bib106","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","article-title":"Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes","volume":"17","author":"Meeks","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1609871","article-title":"Advances in the immunological microenvironment and immunotherapy of bladder cancer","volume":"16","author":"Meng","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib108","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1038\/s41467-025-60654-z","article-title":"Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer","volume":"16","author":"Mizuno","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105275_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155379","article-title":"c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy","volume":"128","author":"Mohan","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.critrevonc.2026.105275_bib110","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.3390\/ijms22062818","article-title":"Cell Therapies in Bladder Cancer Management","volume":"22","author":"Morales","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.critrevonc.2026.105275_bib111","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3390\/cancers17030456","article-title":"Unveiling Prostate-Specific Membrane Antigen\u2019s Potential in Breast Cancer Management","volume":"17","author":"Motta","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105275_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122387","article-title":"Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1\/PD-L1 antibodies","volume":"338","author":"Najafi","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.critrevonc.2026.105275_bib113","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2026.105275_bib114","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3390\/cells9081850","article-title":"DNA Methylation as a Therapeutic Target for Bladder Cancer","volume":"9","author":"Nunes","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105275_bib115","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169241","article-title":"FGFR inhibition augments anti\u2013PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression","volume":"134","author":"Okato","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.critrevonc.2026.105275_bib116","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/01913123.2011.651522","article-title":"CD44s and CD44v6 in Diagnosis and Prognosis of Human Bladder Cancer","volume":"36","author":"Omran","year":"2012","journal-title":"Ultrastruct. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib117","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008429","article-title":"PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion","volume":"12","author":"Ouyang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105275_bib118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1013117","article-title":"Spatiotemporal dynamics of tumor\u2013CAR T-cell interaction following local administration in solid cancers","volume":"21","author":"Owens","year":"2025","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib119","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/imm.13187","article-title":"T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer","volume":"160","author":"Parriott","year":"2020","journal-title":"Immunology"},{"key":"10.1016\/j.critrevonc.2026.105275_bib120","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: The evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105275_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102351","article-title":"The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives","volume":"104","author":"Patelli","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105275_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583716","article-title":"Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring \u201cUniversal\u201d Donor T Cells","volume":"11","author":"Perez","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1455163","article-title":"Oncolytic virus and CAR-T cell therapy in solid tumors","volume":"15","author":"Ponterio","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib124","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00099","article-title":"CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice","volume":"11","author":"Porcellini","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib125","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib126","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-025-07338-4","article-title":"PSMA radioligand uptake correlates with PSMA expression in high-grade glioma and brain metastasis: insights from a prospective PET-MRI guided multiregional biopsy study","author":"Pruis","year":"2025","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"key":"10.1016\/j.critrevonc.2026.105275_bib127","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.874589","article-title":"Tumor-Associated Macrophages Regulate PD-1\/PD-L1 Immunosuppression","volume":"13","author":"Pu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib128","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2504776","article-title":"Research hotspots and frontier analysis of the novel immune checkpoint Nectin-4","volume":"21","author":"Qiao","year":"2025","journal-title":"Hum. Vaccin. & Immunother."},{"key":"10.1016\/j.critrevonc.2026.105275_bib129","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1007\/s00259-024-06973-7","article-title":"68Ga]Ga-PSMA-617 PET\/MRI for imaging patients suspected of hepatocellular carcinoma","volume":"52","author":"Qin","year":"2025","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"key":"10.1016\/j.critrevonc.2026.105275_bib130","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12894-022-01067-8","article-title":"A prognosis marker MUC1 correlates with metabolism and drug resistance in bladder cancer: a bioinformatics research","volume":"22","author":"Qing","year":"2022","journal-title":"BMC Urol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib131","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1002\/ijc.33156","article-title":"Cost of decentralized CAR T-cell production in an academic nonprofit setting","volume":"147","author":"Ran","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105275_bib132","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1377924","article-title":"Efficacy and safety of antibody\u2013drug conjugates in the treatment of urothelial cell carcinoma: a systematic review and meta-analysis of prospective clinical trials","volume":"15","author":"Ren","year":"2024","journal-title":"Front. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105275_bib133","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41571-025-01016-y","article-title":"HER2 testing: evolution and update for a companion diagnostic assay","volume":"22","author":"Robbins","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib134","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1675114","article-title":"Regulatory T cell therapies: from patient data to biological insights","volume":"16","author":"Rodrigues","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib135","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-065X.2008.00608.x","article-title":"Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives","volume":"222","author":"Rodr\u00edguez","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2026.105275_bib136","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01109","article-title":"CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape","volume":"11","author":"Rodriguez-Garcia","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib137","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003354","article-title":"4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells","volume":"9","author":"Roselli","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105275_bib138","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1530541","article-title":"Adoptive cell therapy against tumor immune evasion: mechanisms, innovations, and future directions","volume":"15","author":"Ruan","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib139","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1389971","article-title":"The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review","volume":"15","author":"Satapathy","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib140","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1011885","article-title":"HER2 expression in urothelial carcinoma, a systematic literature review","volume":"12","author":"Scherrer","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib141","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00432-019-03113-9","article-title":"Prostate specific membrane antigen (PSMA) in urothelial cell carcinoma (UCC) is associated with tumor grading and staging","volume":"146","author":"Schreiber","year":"2020","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib142","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib143","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1007\/s00259-022-05701-3","article-title":"A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer","volume":"49","author":"Shang","year":"2022","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"key":"10.1016\/j.critrevonc.2026.105275_bib144","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1560280","article-title":"HER2-positive gastric cancer: from targeted therapy to CAR-T cell therapy","volume":"16","author":"Shao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2023.01.011","article-title":"Construction of CAR-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer","volume":"255","author":"Shen","year":"2023","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.critrevonc.2026.105275_bib146","doi-asserted-by":"crossref","DOI":"10.1049\/htl2.70012","article-title":"An Analysis of Monitoring Solutions for CAR T Cell Production","volume":"12","author":"Shoshi","year":"2025","journal-title":"Healthc. Tech. Lett."},{"key":"10.1016\/j.critrevonc.2026.105275_bib147","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrurol.2015.55","article-title":"Urinary EGFR and EpCAM predict cancer-specific survival","volume":"12","author":"Sidaway","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib148","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1046\/j.1464-410x.1999.00150.x","article-title":"MUC1 mucin as a tumour marker in bladder cancer","volume":"84","author":"Simms","year":"1999","journal-title":"BJU Int."},{"key":"10.1016\/j.critrevonc.2026.105275_bib149","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.3390\/biom15101407","article-title":"Advancing CAR-T Therapy for Solid Tumors: From Barriers to Clinical Progress","volume":"15","author":"Smirnov","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.critrevonc.2026.105275_bib150","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.3390\/ijms26125524","article-title":"Cell-Based Therapies for Solid Tumors: Challenges and Advances","volume":"26","author":"Smolarska","year":"2025","journal-title":"IJMS"},{"key":"10.1016\/j.critrevonc.2026.105275_bib151","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005701","article-title":"Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory B-ALL","volume":"11","author":"Song","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105275_bib152","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105275_bib153","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1071030","article-title":"Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges","volume":"13","author":"Su","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib154","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.3390\/molecules28207033","article-title":"Mucin Glycans: A Target for Cancer Therapy","volume":"28","author":"Sun","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.critrevonc.2026.105275_bib155","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1158\/0008-5472.CAN-12-2217","article-title":"Intratumor Heterogeneity: Evolution through Space and Time","volume":"72","author":"Swanton","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105275_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116532","article-title":"Efficient combination of radiotherapy and CAR-T \u2013 A systematic review","volume":"174","author":"Szlasa","year":"2024","journal-title":"Biomed. & Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105275_bib157","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.950241","article-title":"The Origin and Evolution of Bladder Cancer Stem Cells","volume":"10","author":"Tan","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib158","article-title":"Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia","volume":"14","author":"Tang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib159","first-page":"39","article-title":"TM4SF1 promotes EMT and cancer stemness via the Wnt\/\u03b2-catenin\/SOX2 pathway in colorectal cancer","author":"Tang","year":"2020","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105275_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110158","article-title":"Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma","volume":"119","author":"Tang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib161","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-020-00890-6","article-title":"Gene modification strategies for next-generation CAR T cells against solid cancers","volume":"13","author":"Tian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib162","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105275_bib163","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-024-03028-5","article-title":"A paclitaxel-hyaluronan conjugate (ONCOFID-P-B\u2122) in patients with BCG-unresponsive carcinoma in situ of the bladder: a dynamic assessment of the tumor microenvironment","volume":"43","author":"Tosi","year":"2024","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105275_bib164","doi-asserted-by":"crossref","first-page":"9777","DOI":"10.1038\/s41598-021-89160-0","article-title":"Spotlight on PSMA as a new theranostic biomarker for bladder cancer","volume":"11","author":"Tumedei","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105275_bib165","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1370303","article-title":"Prognostic significance of EGFR, AREG and EREG amplification and gene expression in muscle invasive bladder cancer","volume":"14","author":"Uysal","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib166","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12894-022-01157-7","article-title":"VEGF, EGFR and PSMA as possible imaging targets of lymph node metastases of urothelial carcinoma of the bladder","volume":"22","author":"Van Der Fels","year":"2022","journal-title":"BMC Urol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib167","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines","volume":"87","author":"Van Der Heijden","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib168","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2026.105275_bib169","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-025-01744-9","article-title":"Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?","volume":"18","author":"Vo","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib170","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/genes16040437","article-title":"RON Receptor Signaling and the Tumor Microenvironment","volume":"16","author":"Wachter","year":"2025","journal-title":"Genes"},{"key":"10.1016\/j.critrevonc.2026.105275_bib171","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12967-019-02206-w","article-title":"IL-23 and PSMA-targeted duo-CAR T cells in Prostate Cancer Eradication in a preclinical model","volume":"18","author":"Wang","year":"2020","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.critrevonc.2026.105275_bib172","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41391-021-00394-5","article-title":"Advances in PSMA-targeted therapy for prostate cancer","volume":"25","author":"Wang","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2026.105275_bib173","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002173","article-title":"Fully human antibody VH domains to generate mono and bispecific CAR to target solid tumors","volume":"9","author":"Wang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105275_bib174","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.7150\/thno.105276","article-title":"Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2026.105275_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217616","article-title":"Clinical development of immuno-oncology therapeutics","volume":"617","author":"Wang","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105275_bib176","doi-asserted-by":"crossref","DOI":"10.1093\/jleuko\/qiae141","article-title":"Receptor tyrosine kinase-like orphan receptor serves as a potential target in cancer immunotherapy","volume":"117","author":"Wang","year":"2025","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib177","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41419-024-07245-w","article-title":"RON receptor tyrosine kinase as a critical determinant in promoting tumorigenic behaviors of bladder cancer cells through regulating MMP12 and HIF-2\u03b1 pathways","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105275_bib178","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1097\/CM9.0000000000003803","article-title":"Strategies and challenges in promoting chimeric antigen receptor T cells trafficking and infiltration of solid tumors","volume":"138","author":"Wang","year":"2025","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.critrevonc.2026.105275_bib179","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3390\/pharmaceutics13020166","article-title":"Strategies to Get Drugs across Bladder Penetrating Barriers for Improving Bladder Cancer Therapy","volume":"13","author":"Wang","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105275_bib180","article-title":"Antigen escape in CAR -T therapy: A tumor microenvironment perspective from hematological to solid tumors","volume":"70117","author":"Wang","year":"2025","journal-title":"Int. J. Cancer ijc"},{"key":"10.1016\/j.critrevonc.2026.105275_bib181","article-title":"Latest updates on pathogenesis mechanisms and management strategies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis related to CAR-T cell therapies","author":"Wang","year":"2025","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib182","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12943-024-01952-w","article-title":"Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105275_bib183","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1097\/CM9.0000000000002426","article-title":"Metabolic reprogramming in the immunosuppression of tumor-associated macrophages","volume":"135","author":"Wang","year":"2022","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.critrevonc.2026.105275_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216337","article-title":"Longitudinal detection of subcategorized CD44v6+ CTCs and circulating tumor endothelial cells (CTECs) enables novel clinical stratification and improves prognostic prediction of small cell lung cancer: A prospective, multi-center study","volume":"571","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105275_bib185","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s41423-019-0327-9","article-title":"Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells","volume":"17","author":"Wang","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib186","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.7150\/ijbs.108036","article-title":"From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapy","volume":"21","author":"Wang","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105275_bib187","article-title":"Photostable Cascade-Activatable Peptide Self-Assembly on a Cancer Cell Membrane for High-Performance Identification of Human Bladder Cancer","volume":"35","author":"Wang","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.critrevonc.2026.105275_bib188","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1284722","article-title":"PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells","volume":"6","author":"Wei","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.critrevonc.2026.105275_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103859","article-title":"Chimeric antigen receptor cell therapy: A revolutionary approach transforming cancer treatment to autoimmune disease therapy","volume":"24","author":"Wen","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.critrevonc.2026.105275_bib190","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3892\/ol.2024.14389","article-title":"Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review)","volume":"27","author":"Wu","year":"2024","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2026.105275_bib191","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-025-02033-1","article-title":"Targeting HGF\/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion","volume":"23","author":"Xia","year":"2025","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.critrevonc.2026.105275_bib192","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105275_bib193","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004400","article-title":"PD-L1 blockade restores CAR T cell activity through IFN-\u03b3-regulation of CD163+ M2 macrophages","volume":"10","author":"Yamaguchi","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105275_bib194","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-023-00373-7","article-title":"Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment","volume":"12","author":"Yan","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib195","article-title":"Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression","volume":"16","author":"Yang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105275_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114512","article-title":"Identification and characterization of TM4SF1+ tumor self-seeded cells","volume":"43","author":"Yang","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.critrevonc.2026.105275_bib197","doi-asserted-by":"crossref","DOI":"10.1177\/15330338251336850","article-title":"Bispecific c-Met\/PD-1 CAR-T Cells Have Enhanced Therapeutic Effects on Solid Tumor","volume":"24","author":"Yang","year":"2025","journal-title":"Technol. Cancer Res Treat."},{"key":"10.1016\/j.critrevonc.2026.105275_bib198","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3389\/fimmu.2020.01371","article-title":"Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib199","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3390\/biomedicines9081054","article-title":"Prognostic Significance of ROR2 Expression in Patients with Urothelial Carcinoma","volume":"9","author":"Yeh","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105275_bib200","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11427-016-5024-7","article-title":"Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells","volume":"59","author":"You","year":"2016","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.critrevonc.2026.105275_bib201","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1248","article-title":"Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells in vitro","volume":"10","author":"Yu","year":"2021","journal-title":"Clin. & Trans. Imm"},{"key":"10.1016\/j.critrevonc.2026.105275_bib202","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-017-0444-9","article-title":"Chimeric antigen receptor T cells: a novel therapy for solid tumors","volume":"10","author":"Yu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib203","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216964","article-title":"Tumor-associated macrophage enhances PD-L1-mediated immune escape of bladder cancer through PKM2 dimer-STAT3 complex nuclear translocation","volume":"593","author":"Yu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105275_bib204","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s10637-020-00978-3","article-title":"Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors","volume":"39","author":"Yuan","year":"2021","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.critrevonc.2026.105275_bib205","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3350\/cmh.2024.0934","article-title":"Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma","volume":"31","author":"Zeng","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib206","article-title":"Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib207","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2147\/ITT.S519616","article-title":"Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors","volume":"14","author":"Zhang","year":"2025","journal-title":"ITT"},{"key":"10.1016\/j.critrevonc.2026.105275_bib208","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41419-024-06734-2","article-title":"Molecular understanding and clinical outcomes of CAR T cell therapy in the treatment of urological tumors","volume":"15","author":"Zhang","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105275_bib209","article-title":"Utilizing plasma exchange for severe cytokine release syndrome after CAR-T cell therapy: clinical experience and literature insights","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib210","doi-asserted-by":"crossref","DOI":"10.1002\/cac2.70040","article-title":"Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via deglycosylation of CD47","author":"Zhang","year":"2025","journal-title":"Cancer Commun."},{"key":"10.1016\/j.critrevonc.2026.105275_bib211","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12032-023-02233-0","article-title":"Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment","volume":"41","author":"Zhang","year":"2023","journal-title":"Med Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib212","article-title":"Targeted release of a bispecific fusion protein SIRP\u03b1\/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors","volume":"13","author":"Zhang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105275_bib213","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12935-021-01972-2","article-title":"Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy","volume":"21","author":"Zhang","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.critrevonc.2026.105275_bib214","article-title":"Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform","author":"Zhang","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105275_bib215","doi-asserted-by":"crossref","first-page":"6449","DOI":"10.1097\/JS9.0000000000002662","article-title":"Global clinical trial landscape and therapeutic trends in bladder cancer: a systematic analysis","volume":"111","author":"Zhang","year":"2025","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.critrevonc.2026.105275_bib216","article-title":"CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib217","article-title":"The altering cellular components and function in tumor microenvironment during remissive and relapsed stages of anti-CD19 CAR T-cell treated lymphoma mice","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib218","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.3390\/cancers14174160","article-title":"Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105275_bib219","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CJI.0000000000000505","article-title":"Mucin-1\u2013Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host","volume":"47","author":"Zhou","year":"2024","journal-title":"J. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105275_bib220","article-title":"Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors","volume":"16","author":"Zhu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib221","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1074477","article-title":"Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105275_bib222","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-19897-5","article-title":"p53 and PD-1\/PD-L1 expression contribute to disease progression and are correlated to immune infiltrates in urothelial carcinoma","volume":"15","author":"Zuo","year":"2025","journal-title":"Sci. Rep."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:44:19Z","timestamp":1778481859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":222,"alternative-id":["S1040842826001629"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105275","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress and challenges in CAR-T cell therapy for bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105275"}}